Volume 106, Issue s178 pp. 19-24

Non-cognitive benefits of galantamine (Reminyl^®) treatment in vascular dementia

A. Kurz,

A. Kurz

Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Munich, Germany

Search for more papers by this author

A. Kurz,

A. Kurz

Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Munich, Germany

Search for more papers by this author

First published: 18 December 2002

https://doi.org/10.1034/j.1600-0404.106.s178.5.x

Citations: 6

Alexander Kurz, MD, Professor, Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Moehlstrasse 26, D-81675 Munich, Germany
Tel.: +49 89 4140 4285
Fax: +49 89 4140 4923
e-mail: [email protected]

Share a link

Email
Wechat
Bluesky

Abstract

Vascular dementia (VaD) is a condition that involves deterioration in cognitive and non-cognitive areas. Although cognitive impairment is the defining symptom evaluated during clinical trials, changes in non-cognitive areas such as behavior, global functioning and activities of daily living are assessed because they assist in determining quality of life and overall well-being. Therapy has focused traditionally on preventing and controlling risk factors, as no approved treatments are currently available for these patients. Acetylcholinesterase inhibitors (AChEIs), the treatment of choice in patients with Alzheimer's disease (AD), are a potential treatment option for patients with VaD. Galantamine, an AChEI with nicotinic receptor modulation, has demonstrated clinically relevant benefits (cognition, global functioning, functional ability, behavior) in patients with either AD with cerebrovascular disease (AD with CVD) or probable VaD in a 6-month, randomized, double-blind, placebo-controlled study.

References

1 Gauthier S, Ferris S. Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease. Int J Clin Pract Suppl 2001; 120: 29–39.
PubMed Web of Science® Google Scholar
2 Togashi H, Kimura S, Matsumoto M, Yoshioka M, Minami M, Saito H. Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke 1996; 27: 520–5.
10.1161/01.STR.27.3.520
PubMed Web of Science® Google Scholar
3 Togashi H, Matsumoto M, Yoshioka M, Hirokami M, Minami M, Saito H. Neurochemical profiles in cerebrospinal fluid stroke-prone spontaneously hypertensive rats. Neurosci Lett 1994; 166: 117–20.
10.1016/0304-3940(94)90854-0
CAS PubMed Web of Science® Google Scholar
4 Kimura S, Saito H, Minami M et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 2000; 153: 167–78.
10.1016/S0300-483X(00)00312-7
CAS PubMed Web of Science® Google Scholar
5 Maelicke A. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl™). Int J Clin Pract Suppl 2001; 120: 24–8.
CAS PubMed Web of Science® Google Scholar
6 Erkinjuntti T. Clinical deficits of Alzheimer's disease with cerebrovascular disease and probable VaD. Int J Clin Pract Suppl 2001; 120: 14–23.
PubMed Web of Science® Google Scholar
7 Chui H, Gonthier R. Natural history of vascular dementia. Alzheimer Dis Assoc Disord 1999; 13(Suppl. 3): S124–30.
10.1097/00002093-199912003-00018
PubMed Web of Science® Google Scholar
8 Mendez MF, Younesi FL, Perryman KM. Use of donepezil for vascular dementia: preliminary clinical experience. J Neuropsychiatry Clin Neurosci 1999; 11: 268–70.
10.1176/jnp.11.2.268
CAS PubMed Web of Science® Google Scholar
9 Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia. a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 2001; 8: 361–2.
10.1046/j.1468-1331.2001.00224.x
CAS PubMed Web of Science® Google Scholar
10 Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000; 7: 159–69.
10.1046/j.1468-1331.2000.00046.x
CAS PubMed Web of Science® Google Scholar
11 Samochocki M, Zerlin M, Jostock R et al. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand Suppl 2000; 176: 68–73.
10.1034/j.1600-0404.2000.00310.x
CAS PubMed Web of Science® Google Scholar
12 Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Galantamine is efficacious in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Lancet 2002; 359: 1283–90.
10.1016/S0140-6736(02)08267-3
PubMed Web of Science® Google Scholar
13 Schneider LS, Olin JT, Doody RS et al. Validity and reliability of the Alzheimer's Disease Cooperative Study − Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(Suppl. 2): S22–32.
10.1097/00002093-199700112-00004
PubMed Web of Science® Google Scholar
14 Barclay LL, Zemcov A, Blass JP, Sansone J. Survival in Alzheimer's disease and vascular dementia. Neurology 1985; 35: 834–40.
10.1212/WNL.35.6.834
CAS PubMed Web of Science® Google Scholar
15 Aharon-Peretz J, Kilot D, Tomer R. Behavorial differences between white matter lacunar dementia and Alzheimer's disease: a comparison on the neuropsychiatric inventory. Dement Geriatr Cogn Disord 2000; 11: 294–8.
10.1159/000017252
CAS PubMed Web of Science® Google Scholar
16 Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48: S10–S16.
10.1212/WNL.48.5_Suppl_6.10S
CAS PubMed Web of Science® Google Scholar
17 Kunik ME, Huffman JC, Bharani N et al. Behavorial disturbances in geropsychiatric inpatients across dementia types. J Geriatr Psychiatry Neurol 2000; 13: 49–52.
10.1177/089198870001300108
CAS PubMed Web of Science® Google Scholar
18 Lyketsos CG, Steinberg M, Tschanz JT et al. Mental and behavorial disturbances in dementia: findings from the Cache county study on memory and aging. Am J Psychiatry 2000; 157: 708–14.
10.1176/appi.ajp.157.5.708
CAS PubMed Web of Science® Google Scholar
19 Lehfeld H, Reisberg B, Finkel S et al. Informant-rated activities-of-daily-living (ADL) assessments: results of a study of 141 items in the USA, Germany, Russia, and Greece for the International ADL Scale Development Project. Alzheimer Dis Assoc Disord 1997; 11: S39–44.
PubMed Web of Science® Google Scholar
20 Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999; 53: 471–81.
10.5014/ajot.53.5.471
CAS PubMed Web of Science® Google Scholar
21 Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269–76.
10.1212/WNL.54.12.2269
CAS PubMed Web of Science® Google Scholar
22 Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261–8.
10.1212/WNL.54.12.2261
CAS PubMed Web of Science® Google Scholar
23 Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000; 321: 1445–9.
10.1136/bmj.321.7274.1445
CAS PubMed Google Scholar
24 Torfs K, Feldman H. 12-Month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease: two randomized placebo-controlled studies. Poster presented at the World Alzheimer Congress, Washington, DC; 2000.
Google Scholar
25 Schulz R, Beach SR. Caregiving as a risk factor for mortality. JAMA 1999; 23: 2215–9.
10.1001/jama.282.23.2215
Web of Science® Google Scholar
26 Bullock R, Lilienfeld S. Galantamine shows promising results in probable vascular dementia and Alzheimer's disease with cerebrovascular components. Poster presented at. XVII. World Congress of Neurology, London, UK; 2001.
Google Scholar

Citing Literature

All articles

Non-cognitive benefits of galantamine (Reminyl^®) treatment in vascular dementia

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Non-cognitive benefits of galantamine (Reminyl®) treatment in vascular dementia

Abstract

References

Citing Literature

References

Related

Information

Non-cognitive benefits of galantamine (Reminyl^®) treatment in vascular dementia